warning

Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Title  
LCI-GU-URO-CRI-001: A Phase II Study of Crizotinib in Patients with c-MET or RON-Positive Metastatic Urothelial Cancer
Brief Description  
Primary: To assess the overall response rate (ORR) of crizotinib in patients with c-MET or RON-positive advanced urothelial carcinoma previously treated with a platinum-based regimen. Secondary: To assess overall survival (OS), progression-free survival (PFS), and the safety and toxicity profile with this regimen. Exploratory: To correlate c-MET and RON expression patterns with response rate, PFS, and OS, and to perform additional genomic analysis on select patients in the future.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Urinary Bladder
Status  
OPEN
Start Date  
02/15/2016
IRB Number  
00015549
Principal Investigator  
Burgess, Earle Frederick
Contact Name  
Sandy L Pollock

For More Information, Contact  Sandy  L, Pollock
Phone:  980-993-5418 Fax:    
Email:  Sandy.Pollock@carolinashealthcare.org
Address:1550 Faulk Street Suite 1500 Monroe, NC 28112
Close